Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials

Human epidermal growth factor receptor (HER2) is overexpressed and/or amplified in approximately 15% –20% of early breast cancer patients[1] and is correlated with a worse prognosis. As an anti-HER2 humanized monoclonal antibody, trastuzumab can significantly reduce the risk of recurrence and improve the prognoses of HER2-positive patients[2–6]. According to a Cochrane meta-analysis, trastuzuma b confers a reduction in mortality by one-third, in relapse rate of 40%, in combination with (neo)adjuvant chemotherapy[7].

Source: Cancer Treatment Reviews - February 28, 2019 Category: Cancer & Oncology Authors: Lujia Chen, Wenqi Zhou, Xiaolei Hu, Man Yi, Changsheng Ye, Guangyu Yao Tags: Systematic or Meta-analysis Studies Source Type: research